Placebo Controlled Trial of Bosentan for SAPAH
ID Number 07-0598Principal Investigator(s)
Maria L. Padilla
Department(s) or Division(s)
Pulmonary, Critical Care and Sleep Medicine
The purpose of this research study is to see if bosentan is safe and effective in the treatment of sarcoidosis associated pulmonary hypertension. The US Food and Drug Administration (FDA) have approved it for treatment of several forms of pulmonary hypertension. However, the use of bosentan in the treatment of sarcoidosis associated pulmonary hypertension is not approved by the FDA.
Recruiting Patients: No